İlaç Erupsiyonları

Öz

İlaç erupsiyonu önemli bir sağlık sorunudur. Çoğu ilaç erupsiyonu hafif seyrederken, bazıları hayatı tehdit edici özellikte, çok az bir kısmı da ölümcül olabilmektedir. İlaç erupsiyonları her türlü dermatozu taklit edebilir. Tüm güçlüklere rağmen ilaç erüpsiyonu tanısı esas olarak klinik bulgulara dayanır. Klinik yaklaşımda esas olan ilaç ilişkisinin ortaya konmasıdır. Bu açıdan yapılacak bir nedensellik değerlendirmesi için Naronjo İlaç Yan Etki Olasılık Ölçeği ve Dünya Sağlık Örgütü - Uppsala İzlem Merkezi’ne ait Nedensellik Değerlendirme Sistemi gibi geliştirilmiş birtakım ölçekler vardır. Reaksiyon şüphesi olan olgularda kullanılmalıdır. İlaç reaksiyonlarında öncelikli yaklaşım önlenmesine yönelik çalışmalara ağırlık verilmesidir. Bunun için mutlak ihtiyaç olmadıkça ilaçlar kullanılmamalı, toplum bu konuda tekrar tekrar bilgilendirilmeli ve akılcı ilaç kullanımına önem verilmelidir.

Anahtar Kelimeler

• ilaç erupsiyonu,nedensellik değerlendirmesi

Drug Eruptions

Öz

Drug eruption is a major health problem. While most drug eruptions are mild, self-limited, some has life-threatening potentional and a very small number of it may be fatal. Drug eruptions can mimic any kind of dermatoses. Despite all the difficulties the diagnosis of drug eruption is mainly based on clinical findings. What’s essential in clinical approach is to show the association between the drug and the eruption. There’s a few causality assessment scales such as “Naranjo Adverse Drug Reaction Probability Scale” and “Causality Assessment provided by World Health Organization-Uppsala Monitoring Centre” should be used if there’s any suspicion. Prevention should be a priority while dealing with drug reactions. Drugs should not be used unless absolutely necessary, society should be informed repeatedly and the importance of rational drug use should always be kept on the agenda. 

Anahtar Kelimeler

• drug eruptions,causality assessment

Kaynakça

1. 1. Bachot N , Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. American journal of clinical dermatology 2003;4:561-72.
2. 2. Svensson CK, Cowen EW , Gaspari AA. Cutaneous drug reactions. Pharmacological reviews 2001;53:357-79.
3. 3. DeLeo VA. Skin testing in systemic cutaneous drug reactions. Lancet 1998;352:1488-90.
4. 4. Bigby M. Rates of cutaneous reactions to drugs. Archives of dermatology 2001;137:765-70.
5. 5. Pudukadan D , Thappa DM. Adverse cutaneous drug reactions: clinical pattern and causative agents in a tertiary care center in South India. Indian journal of dermatology, venereology and leprology 2004;70:20-4.
6. 6. Stern RS. Clinical practice. Exanthematous drug eruptions. The New England journal of medicine 2012;366:2492-501.
7. 7. Warnock JK , Morris DW. Adverse cutaneous reactions to antidepressants. American journal of clinical dermatology 2002;3:329-39.
8. 8. Lazarou J, Pomeranz BH , Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA : the journal of the American Medical Association 1998;279:1200-5.

9. 9. Liao PJ, Shih CP, Mao CT, Deng ST, Hsieh MC , Hsu KH. The cutaneous adverse drug reactions: risk factors, prognosis and economic impacts. International journal of clinical practice 2013;67:576-84.
10. 10. U.S. Department of Health & Human Services F. Preventable Adverse Drug Reactions: A Focus on Drug Interactions2009.
11. 11. Wolf R , Davidovici B. Severe cutaneous adverse drug reactions: who should treat, where and how?: Facts and controversies. Clinics in dermatology 2010;28:344-8.
12. 12. Hiware S, Shrivastava M, Mishra D, Mukhi J , Puppalwar G. Evaluation of Cutaneous Drug Reactions in Patients Visiting Out Patient Departments of Indira Gandhi Government Medical College and Hospital (IGGMC and H), Nagpur. Indian journal of dermatology 2013;58:18-21.
13. 13. Roujeau JC , Stern RS. Severe adverse cutaneous reactions to drugs. The New England journal of medicine 1994;331:1272-85.
14. 14. Edwards IR , Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet (London, England) 2000;356:1255-9.
15. 15. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al. A method for estimating the probability of adverse drug reactions. Clinical pharmacology and therapeutics 1981;30:239-45.
16. 16. Justiniano H, Berlingeri-Ramos AC , Sanchez JL. Pattern analysis of drug-induced skin diseases. The American Journal of dermatopathology 2008;30:352-69.
17. 17. Weyers W , Metze D. Histopathology of drug eruptions - general criteria, common patterns, and differential diagnosis. Dermatology practical & conceptual 2011;1:33-47.
18. 18. Crowson AN, Brown TJ , Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions : implications for management. American journal of clinical dermatology 2003;4:407-28.
19. 19. Breathnach SM. Adverse cutaneous reactions to drugs. Clinical medicine (London, England) 2002;2:15-9.
20. 20. Lee AY. Fixed drug eruptions. Incidence, recognition, and avoidance. American journal of clinical dermatology 2000;1:277-85.
21. 21. Hausermann P, Harr T , Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact dermatitis 2004;51:297-310.
22. 22. Aquino M , Rosner G. Systemic Contact Dermatitis. Clinical reviews in allergy & immunology 2018.
23. 23. Wolf R, Orion E , Matz H. The baboon syndrome or intertriginous drug eruption: a report of eleven cases and a second look at its pathomechanism. Dermatology online journal 2003;9:2.
24. 24. Fritsch PO , Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. American journal of clinical dermatology 2000;1:349-60.
25. 25. Harr T , French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet journal of rare diseases 2010;5:39.
26. 26. Walsh SA , Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clinical and experimental dermatology 2011;36:6-11.
27. 27. Bocquet H, Bagot M , Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Seminars in cutaneous medicine and surgery 1996;15:250-7.
28. 28. Ghislain PD, Bodarwe AD, Vanderdonckt O, Tennstedt D, Marot L , Lachapelle JM. Drug-induced eosinophilia and multisystemic failure with positive patch-test reaction to spironolactone: DRESS syndrome. Acta dermato-venereologica 2004;84:65-8.
29. 29. Goel A , Walia RL. Pseudolymphoma syndrome revisited. Indian journal of dermatology, venereology and leprology 2004;70:48-51.
30. 30. Kano Y, Inaoka M , Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Archives of dermatology 2004;140:183-8.
31. 31. Harman KE, Morris SD , Higgins EM. Persistent anticonvulsant hypersensitivity syndrome responding to ciclosporin. Clinical and experimental dermatology 2003;28:364-5.
32. 32. Ghislain PD , Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatology online journal 2002;8:5.
33. 33. Bhargava P. Anticonvulsant hypersensitivity syndrome study of 60 cases. Indian journal of dermatology, venereology and leprology 2001;67:317-9.
34. 34. Aihara Y, Ito SI, Kobayashi Y, Yamakawa Y, Aihara M , Yokota S. Carbamazepine-induced hypersensitivity syndrome associated with transient hypogammaglobulinaemia and reactivation of human herpesvirus 6 infection demonstrated by real-time quantitative polymerase chain reaction. The British journal of dermatology 2003;149:165-9.
35. 35. Revuz J. New advances in severe adverse drug reactions. Dermatologic clinics 2001;19:697-709, ix.
36. 36. Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S et al. Cellular and molecular pathophysiology of cutaneous drug reactions. American journal of clinical dermatology 2002;3:229-38.
37. 37. Choi TS, Doh KS, Kim SH, Jang MS, Suh KS , Kim ST. Clinicopathological and genotypic aspects of anticonvulsant-induced pseudolymphoma syndrome. The British journal of dermatology 2003;148:730-6.
38. 38. Thappa DM , Sethuraman G. Dapsone (sulfone) syndrome (CME). Indian journal of dermatology, venereology and leprology 2000;66:117-20.
39. 39. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? The British journal of dermatology 2007;156:609-11.
40. 40. Shiohara T, Iijima M, Ikezawa Z , Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. The British journal of dermatology 2007;156:1083-4.
41. 41. Heinemann C, Wiesend CL, Hipler C, Norgauer J , Ziemer M. Acute generalized exanthematous pustulosis (AGEP) after oral use of amphotericin B. Journal of the American Academy of Dermatology 2007;57:S61-3.
42. 42. Britschgi M, Steiner UC, Schmid S, Depta JP, Senti G, Bircher A et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. The Journal of clinical investigation 2001;107:1433-41.
43. 43. Kwah YC , Leow YH. Not all pustules are infective in nature: acute generalised exanthematous pustulosis causing pustular eruptions in an elderly woman. Singapore medical journal 2005;46:349-51.
44. 44. Mengesha YM , Bennett ML. Pustular skin disorders: diagnosis and treatment. American journal of clinical dermatology 2002;3:389-400.
45. 45. Witkowski JA , Parish LC. Cutaneous reactions to antibacterial agents. Skinmed 2002;1:33-44.
46. 46. Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Archives of dermatology 1991;127:1333-8.
47. 47. Manders SM. Serious and life-threatening drug eruptions. American family physician 1995;51:1865-72.